Heterogeneity of Large Cell Carcinoma of the Lung | Zendy

Mattia Barbareschi | Zendy; Chiara Cantaloni | Zendy; Valerio Del Vescovo | Zendy; Alberto Cavazza | Zendy; Valentina Monica | Zendy; Rodolfo Carella | Zendy; Giulio Rossi | Zendy; Luca Morelli | Zendy; Alberto Cucino | Zendy; Massimo Silvestri | Zendy; Giuseppe Tirone | Zendy; Giuseppe Pelosi | Zendy; Paolo Graziano | Zendy; Mauro Papotti | Zendy; Paolo Palma | Zendy; Claudio Doglioni | Zendy; Michela A. Denti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Heterogeneity of Large Cell Carcinoma of the Lung

Author(s) -

Mattia Barbareschi,

Chiara Cantaloni,

Valerio Del Vescovo,

Alberto Cavazza,

Valentina Monica,

Rodolfo Carella,

Giulio Rossi,

Luca Morelli,

Alberto Cucino,

Massimo Silvestri,

Giuseppe Tirone,

Giuseppe Pelosi,

Paolo Graziano,

Mauro Papotti,

Paolo Palma,

Claudio Doglioni,

Michela A. Denti

Publication year - 2011

Publication title -

american journal of clinical pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.859

H-Index - 128

eISSN - 1943-7722

pISSN - 0002-9173

DOI - 10.1309/ajcpyy79xagraycj

Subject(s) - cytokeratin , adenocarcinoma , immunohistochemistry , pathology , lung cancer , medicine , lung , carcinoma , microrna , clinical significance , oncology , biology , cancer , gene , biochemistry

Large cell carcinomas (LCCs) of the lung are heterogeneous and may be of different cell lineages. We analyzed 56 surgically resected lung tumors classified as LCC on the basis of pure morphologic grounds, using a panel of immunophenotypic markers (adenocarcinoma [ADC]-specific, thyroid transcription factor-1, cytokeratin 7, and napsin A; squamous cell carcinoma [SQCC]-specific, p63, cytokeratin 5, desmocollin 3, and Δnp63) and the quantitative analysis of microRNA-205 (microRNA sample score [mRSS]). Based on immunoprofiles 19 (34%) of the cases were reclassified as ADC and 14 (25%) as SQCC; 23 (41%) of the cases were unclassifiable. Of these 23 cases, 18 were classified as ADC and 5 as SQCC according to the mRSS. Our data show that an extended panel of immunohistochemical markers can reclassify around 60% of LCCs as ADC or SQCC. However, a relevant percentage of LCCs may escape convincing immunohistochemical classification, and mRSS could be used for further typing, but its clinical relevance needs further confirmation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research